BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li G, Tian Y, Zhu WG. The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy. Front Cell Dev Biol 2020;8:576946. [PMID: 33117804 DOI: 10.3389/fcell.2020.576946] [Cited by in Crossref: 9] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Tulsyan S, Aftab M, Sisodiya S, Khan A, Chikara A, Tanwar P, Hussain S. Molecular basis of epigenetic regulation in cancer diagnosis and treatment. Front Genet 2022;13:885635. [DOI: 10.3389/fgene.2022.885635] [Reference Citation Analysis]
2 Sundaramurthi H, Giricz Z, Kennedy BN. Evaluation of the Therapeutic Potential of Histone Deacetylase 6 Inhibitors for Primary and Metastatic Uveal Melanoma. Int J Mol Sci 2022;23:9378. [PMID: 36012642 DOI: 10.3390/ijms23169378] [Reference Citation Analysis]
3 Ahmed S, Alam W, Jeandet P, Aschner M, Alsharif KF, Saso L, Khan H. Therapeutic Potential of Marine Peptides in Prostate Cancer: Mechanistic Insights. Marine Drugs 2022;20:466. [DOI: 10.3390/md20080466] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kim J, Lee H, Yi S, Kim K. Gene regulation by histone-modifying enzymes under hypoxic conditions: a focus on histone methylation and acetylation. Exp Mol Med. [DOI: 10.1038/s12276-022-00812-1] [Reference Citation Analysis]
5 Park J, Lee K, Kim K, Yi SJ. The role of histone modifications: from neurodevelopment to neurodiseases. Signal Transduct Target Ther 2022;7:217. [PMID: 35794091 DOI: 10.1038/s41392-022-01078-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Tan SYX, Zhang J, Tee WW. Epigenetic Regulation of Inflammatory Signaling and Inflammation-Induced Cancer. Front Cell Dev Biol 2022;10:931493. [PMID: 35757000 DOI: 10.3389/fcell.2022.931493] [Reference Citation Analysis]
7 Foster AC, Jacques BE, Piu F. Hearing loss: The final frontier of pharmacology. Pharmacol Res Perspect 2022;10:e00970. [PMID: 35599339 DOI: 10.1002/prp2.970] [Reference Citation Analysis]
8 Rahbari R, Rasmi Y, Khadem-Ansari MH, Abdi M. The role of histone deacetylase 3 in breast cancer. Med Oncol 2022;39:84. [PMID: 35578147 DOI: 10.1007/s12032-022-01681-4] [Reference Citation Analysis]
9 Geurs S, Clarisse D, Baele F, Franceus J, Desmet T, De Bosscher K, D'hooghe M. Identification of mercaptoacetamide-based HDAC6 inhibitors via a lean inhibitor strategy: screening, synthesis, and biological evaluation. Chem Commun (Camb) 2022. [PMID: 35510683 DOI: 10.1039/d2cc01550a] [Reference Citation Analysis]
10 Azlan A, Rajasegaran Y, Kang Zi K, Rosli AA, Yik MY, Yusoff NM, Heidenreich O, Moses EJ. Elucidating miRNA Function in Cancer Biology via the Molecular Genetics’ Toolbox. Biomedicines 2022;10:915. [DOI: 10.3390/biomedicines10040915] [Reference Citation Analysis]
11 Dhuguru J, Ghoneim OA. Quinazoline Based HDAC Dual Inhibitors as Potential Anti-Cancer Agents. Molecules 2022;27:2294. [PMID: 35408693 DOI: 10.3390/molecules27072294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Gomez-Sanchez JA, Patel N, Martirena F, Fazal SV, Mutschler C, Cabedo H. Emerging Role of HDACs in Regeneration and Ageing in the Peripheral Nervous System: Repair Schwann Cells as Pivotal Targets. Int J Mol Sci 2022;23:2996. [PMID: 35328416 DOI: 10.3390/ijms23062996] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Sun L, Zhang J, Wen K, Huang S, Li D, Xu Y, Wu J. The Prognostic Value of Lysine Acetylation Regulators in Hepatocellular Carcinoma. Front Mol Biosci 2022;9:840412. [DOI: 10.3389/fmolb.2022.840412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Clauß O, Schäker-hübner L, Wenzel B, Toussaint M, Deuther-conrad W, Gündel D, Teodoro R, Dukić-stefanović S, Ludwig F, Kopka K, Brust P, Hansen FK, Scheunemann M. Development and Biological Evaluation of the First Highly Potent and Specific Benzamide-Based Radiotracer [18F]BA3 for Imaging of Histone Deacetylases 1 and 2 in Brain. Pharmaceuticals 2022;15:324. [DOI: 10.3390/ph15030324] [Reference Citation Analysis]
15 Bag A, Schultz A, Bhimani S, Stringfield O, Dominguez W, Mo Q, Cen L, Adeegbe D. Coupling the immunomodulatory properties of the HDAC6 inhibitor ACY241 with Oxaliplatin promotes robust anti-tumor response in non-small cell lung cancer. Oncoimmunology 2022;11:2042065. [PMID: 35223194 DOI: 10.1080/2162402X.2022.2042065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Zeyen P, Zeyn Y, Herp D, Mahmoudi F, Yesiloglu TZ, Erdmann F, Schmidt M, Robaa D, Romier C, Ridinger J, Herbst-gervasoni CJ, Christianson DW, Oehme I, Jung M, Krämer OH, Sippl W. Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114272] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Salazar-González RA, Doll MA, Hein DW. Arylamine N-Acetyltransferase 1 Activity is Regulated by the Protein Acetylation Status. Front Pharmacol 2022;13:797469. [PMID: 35153780 DOI: 10.3389/fphar.2022.797469] [Reference Citation Analysis]
18 Özel M, Başkol G, Başkol M, Güneş F, Uçar Ç, Doğru BN, Akalın H. SAHA induce hippo pathway in CCA cells without increasing cell proliferation. Mol Biol Rep 2022. [PMID: 35112301 DOI: 10.1007/s11033-022-07204-8] [Reference Citation Analysis]
19 Yuan B, Zhao X, Wang X, Liu E, Liu C, Zong Y, Jiang Y, Hou M, Chen Y, Chen L, Zhang Y, Wang H, Fu J. Patient‐derived organoids for personalized gallbladder cancer modelling and drug screening. Clinical & Translational Med 2022;12. [DOI: 10.1002/ctm2.678] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Voss SR, Smith JJ, Cecil RF, Kabangu M, Duerr TJ, Monaghan JR, Timoshevskaya N, Ponomareva LV, Thorson JS, Veliz-Cuba A, Murrugarra D. HDAC Inhibitor Titration of Transcription and Axolotl Tail Regeneration. Front Cell Dev Biol 2021;9:767377. [PMID: 35036404 DOI: 10.3389/fcell.2021.767377] [Reference Citation Analysis]
21 Ruzic D, Djoković N, Srdić-rajić T, Echeverria C, Nikolic K, Santibanez JF. Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention. Pharmaceutics 2022;14:209. [DOI: 10.3390/pharmaceutics14010209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
22 Dai E, Zhu Z, Wahed S, Qu Z, Storkus WJ, Guo ZS. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Mol Cancer 2021;20. [DOI: 10.1186/s12943-021-01464-x] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
23 Huang G, Chen J, Zhou J, Xiao S, Zeng W, Xia J, Zeng X. Epigenetic modification and BRAF gene mutation in thyroid carcinoma. Cancer Cell Int 2021;21. [DOI: 10.1186/s12935-021-02405-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Ali A, Ali A, Khan S, Ibrahim M, Alshehri MA, Thirupathi A. Inhibition of HDACs Suppresses Cell Proliferation and Cell Migration of Gastric Cancer by Regulating E2F5 Targeting BCL2. Life (Basel) 2021;11:1425. [PMID: 34947956 DOI: 10.3390/life11121425] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Malat P, Ekalaksananan T, Heawchaiyaphum C, Suebsasana S, Roytrakul S, Yingchutrakul Y, Pientong C. Andrographolide Inhibits Lytic Reactivation of Epstein-Barr Virus by Modulating Transcription Factors in Gastric Cancer. Microorganisms 2021;9:2561. [PMID: 34946164 DOI: 10.3390/microorganisms9122561] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Lu Y, Sun D, Xiao D, Shao Y, Su M, Zhou Y, Li J, Zhu S, Lu W. Design, Synthesis, and Biological Evaluation of HDAC Degraders with CRBN E3 Ligase Ligands. Molecules 2021;26:7241. [PMID: 34885822 DOI: 10.3390/molecules26237241] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Samuelov L, Bochner R, Magal L, Malovitski K, Sagiv N, Nousbeck J, Keren A, Fuchs-Telem D, Sarig O, Gilhar A, Sprecher E. Vorinostat, a histone deacetylase inhibitor, as a potential novel treatment for psoriasis. Exp Dermatol 2021. [PMID: 34787924 DOI: 10.1111/exd.14502] [Reference Citation Analysis]
28 Halasa M, Adamczuk K, Adamczuk G, Afshan S, Stepulak A, Cybulski M, Wawruszak A. Deacetylation of Transcription Factors in Carcinogenesis. Int J Mol Sci 2021;22:11810. [PMID: 34769241 DOI: 10.3390/ijms222111810] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Burkitt K, Saloura V. Epigenetic Modifiers as Novel Therapeutic Targets and a Systematic Review of Clinical Studies Investigating Epigenetic Inhibitors in Head and Neck Cancer. Cancers (Basel) 2021;13:5241. [PMID: 34680389 DOI: 10.3390/cancers13205241] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
30 Wachholz V, Mustafa AM, Zeyn Y, Henninger SJ, Beyer M, Dzulko M, Piée-Staffa A, Brachetti C, Haehnel PS, Sellmer A, Mahboobi S, Kindler T, Brenner W, Nikolova T, Krämer OH. Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3. Arch Toxicol 2021. [PMID: 34665271 DOI: 10.1007/s00204-021-03174-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, Shu P, Li D, Wang Y. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther 2021;6:362. [PMID: 34620838 DOI: 10.1038/s41392-021-00670-9] [Cited by in F6Publishing: 23] [Reference Citation Analysis]
32 Li F, Wang D, Wang H, Chen L, Sun X, Wan Y. Inhibition of HDAC1 alleviates monocrotaline-induced pulmonary arterial remodeling through up-regulation of miR-34a. Respir Res 2021;22:239. [PMID: 34465322 DOI: 10.1186/s12931-021-01832-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Zhu H, Liu X. Advances of Tumorigenesis, Diagnosis at Early Stage, and Cellular Immunotherapy in Gastrointestinal Malignancies. Front Oncol 2021;11:666340. [PMID: 34434889 DOI: 10.3389/fonc.2021.666340] [Reference Citation Analysis]
34 Marx C, Sonnemann J, Beyer M, Maddocks ODK, Lilla S, Hauzenberger I, Piée-Staffa A, Siniuk K, Nunna S, Marx-Blümel L, Westermann M, Wagner T, Meyer FB, Thierbach R, Mullins CS, Kdimati S, Linnebacher M, Neri F, Heinzel T, Wang ZQ, Krämer OH. Mechanistic insights into p53-regulated cytotoxicity of combined entinostat and irinotecan against colorectal cancer cells. Mol Oncol 2021. [PMID: 34258881 DOI: 10.1002/1878-0261.13060] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
35 Chen L, Fei Y, Zhao Y, Chen Q, Chen P, Pan L. Expression and prognostic analyses of HDACs in human gastric cancer based on bioinformatic analysis. Medicine (Baltimore) 2021;100:e26554. [PMID: 34232196 DOI: 10.1097/MD.0000000000026554] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Chianese A, Santella B, Ambrosino A, Stelitano D, Rinaldi L, Galdiero M, Zannella C, Franci G. Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives. Cancers (Basel) 2021;13:2761. [PMID: 34199429 DOI: 10.3390/cancers13112761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
37 Hayes AJ, Melrose J. What Are the Potential Roles of Nuclear Perlecan and Other Heparan Sulphate Proteoglycans in the Normal and Malignant Phenotype. Int J Mol Sci 2021;22:4415. [PMID: 33922532 DOI: 10.3390/ijms22094415] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
38 Keenan EK, Zachman DK, Hirschey MD. Discovering the landscape of protein modifications. Mol Cell 2021;81:1868-78. [PMID: 33798408 DOI: 10.1016/j.molcel.2021.03.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
39 Zhang XH, Kang HQ, Tao YY, Li YH, Zhao JR, Ya-Gao, Ma LY, Liu HM. Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity. Eur J Med Chem 2021;218:113392. [PMID: 33831778 DOI: 10.1016/j.ejmech.2021.113392] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
40 Wu CP, Hung CY, Lusvarghi S, Chang YF, Hsiao SH, Huang YH, Hung TH, Yu JS, Ambudkar SV. Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat. Int J Mol Sci 2021;22:2592. [PMID: 33807514 DOI: 10.3390/ijms22052592] [Cited by in F6Publishing: 3] [Reference Citation Analysis]